Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Aerovate Therapeutics Q3 EPS $(0.56) Misses $(0.50) Estimate

Aerovate Therapeutics (NASDAQ:AVTE) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.50) by 12 percent. This is a 115.38 percent decrease over losses of $(0.26) per share
byBenzinga Newsdesk
November 14, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Aerovate Therapeutics (NASDAQ:AVTE) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.50) by 12 percent. This is a 115.38 percent decrease over losses of $(0.26) per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Earnings Outlook For Travere Therapeutics

By Benzinga Insights
October 26, 3:32 PM
Travere Therapeutics (NASDAQ:TVTX) is set to give its latest quarterly earnings report on Thursday, 2022-10-27. Here's what investors need to know before the announcement. Analysts estimate that Travere Therapeutics will report an earnings per share (EPS) of $-0.89.

TVTX